Liquid biopsy companies dominating biotech VC funding
The latest issue of GEN summarizes the VC activity in the biotech space for 2017 so far. There were 205 deals through the end of Q2 in which a total of $4.697B was raised. Three genomics companies alone accounted for $1.335B of that total: GRAIL = $900M (Q1) Guardant Health = $360M (Q2) WuXi NextCode…